Biogen (BIIB)
(Real Time Quote from BATS)
$209.41 USD
+6.95 (3.43%)
Updated Apr 26, 2024 02:14 PM ET
3-Hold of 5 3
C Value F Growth A Momentum D VGM
Price, Consensus and EPS Surprise
BIIB 209.41 +6.95(3.43%)
Will BIIB be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for BIIB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BIIB
Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates
The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
BIIB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX
Stock Market News for Apr 25, 2024
Biogen (BIIB) Q1 Earnings Beat, Stock Up on Alzheimer Drug Uptake
Other News for BIIB
Biogen’s Financial Upswing: Strong Q1 Performance and Market Penetration Justify Buy Rating
BIIB June 7th Options Begin Trading
Sage Therapeutics price target lowered by $11 at RBC Capital, here's why
Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Dexcom (DXCM) and Herbalife (HLF)
Buy Rating Justified: Biogen’s Promising Drug Launches and Strategic Growth Initiatives